Aridis is a privately held biotechnology company focused on infectious diseases located in San Jose, CA, USA. Aridis has a strong portfolio of anti-infective product candidates and best-in-clase formulation platform technologies available for partnering. Aridis has raised over $8m in grant funding from leading institutions such asthe National Institutes of Health, USAID, PATH/Gates Foundations, and Regional Centers of Excellence, etc.

PRODUCT CANDIDATES:

Aerucin^TM is a human monoclonal antibody that kills Pseudomonas aeruginosa and has demonstrated efficacy against lung and blood-borne infections in preclinical animal testing

Panaecin^TM is a small molecule with broad spectrum anti-infective activity against gram negative and positive bacteria, fungi and protozoa including multi-drug resistant bacteria and those residing in biofolms

Rotavax^TM combines Aridis’ unique delivery system with a rotavirus vaccine with phase II clinical efficacy data demonstrating strong protection against gastroenteritis in infants.

PLATFORM TECHNOLOGIES:

Formulation technologies that can stabilize complex biopharmaceuticals at room temperature and above

 

Delivery technologies that can aerosolize therapeutic compounds for lung delivery and orally deliver vaccines on quick-dissolving thin films